A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

Annals of Oncology

Volumn 28, Issue 2, 2017, Pages 313-320

  Martín, Miguel ^a   Chan, A ^b   Dirix, L ^c   O'Shaughnessy, J ^d   Hegg, R ^e   Manikhas, A ^f   Shtivelband, M ^g   Krivorotko, P ^h   Batista Lopez N ⁱ   Campone, M ^j   Ruiz Borrego, M ^k   Khan, Q J ^l   Beck, J T ^m   Ramos Vazquez M ⁿ   Urban, P ^o   Goteti, S ^o   Di Tomaso, E ^p   Massacesi, C ^q   Delaloge, S ^r  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CURTIN UNIVERSITY   (Australia)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d TEXAS ONCOLOGY   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f City Clinical Oncology Dispensary   (Russian Federation)

^g Clinical Oncology Hematology   (United States)

^h N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

ⁱ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^j Nantes René Gauducheau Centrede Recherche en Cancérologie ^*  (France)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^m Highlands Oncology Group   (United States)

ⁿ Centro Oncologico de Galicia   (Spain)

^o NOVARTIS PHARMA AG   (Switzerland)

^p NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^q Novartis Oncology   (France)

^r INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Advanced breast cancer; Buparlisib (BKM120); HER2 breast cancer; Paclitaxel; PI3K pathway

Indexed keywords

BUPARLISIB; PACLITAXEL; PLACEBO; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; NVP-BKM120; PHOSPHATIDYLINOSITOL 3 KINASE;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE; GENE MUTATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PIK3CA GENE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PTEN GENE; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MORPHOLINES; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019587899     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw562     Document Type: Article

References (20)

1. Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014; 25: 1871-1888.
2. National Comprehensive Cancer Network. Breast cancer: NCCN clinical practice guidelines in oncology v3. 2015.
3. Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013; 2013: 137414.
4. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
5. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
6. Huang W-C, Hung M-C. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009; 108: 180-194.
7. Hu L, Hofmann J, Lu Y et al. Inhibition of phosphatidylinositol 30-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092.
8. Maira S-M, Pecchi S, Huang A et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11: 317-328.
9. Rodon J, Braña I, Siu LL et al. Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014; 32: 670-681.
10. Dirix L, Schuler M, Machiels J et al. Phase Ib dose-escalation study of BEZ235 or BKM120 in combination with paclitaxel (PTX) in patients with advanced solid tumors. Ann Oncol 2012; 23(Suppl 9): Abstr 454P.
11. Brannath W, Zuber E, Branson M et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 2009; 28: 1445-1463.
12. Vuylsteke P, Huizing M, Petrakova K et al. PEGGY: a phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC). Eur J Cancer 2015; 51(Suppl 3): abstr 1803.
13. Goteti S, Hirawat S, Massacesi C et al. Some practical considerations for phase III studies with biomarker evaluations. J Clin Oncol 2014; 32: 854-855.
14. Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012; 17: 205-216.
15. Yates LR, Gerstung M, Knappskog S et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. NatMed 2015; 21: 751-759.
16. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
17. Gradishar WJ, Kaklamani V, Sahoo TP et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013; 49: 312-322.
18. Crown J, O'Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012; 23(Suppl): vi56-vi56.65.
19. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/ mTOR pathways. Pharmacogenomics Pers Med 2014; 7: 203-215.
20. Bosch A, Li Z, Bergamaschi A et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015; 7: 283ra51.